Clinical Management of Stable Coronary Artery Disease (CAD) in Patients with T2D
Listen to members of the writing group for the new AHA statement on the clinical management of stable coronary artery disease in patients with T2D. The statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2D, with emphasis on the emerging evidence.
Dr. Suzanne Arnold, Chair, and fellow writing group members, Dr. Prakash Deedwania and Dr. Mikhail Kosiborod will review highlights from the statement, including recent clinical trials which uncovered several new drugs that not only reduce glucose, but also improve cardiovascular and renal outcomes (Clinical Management of Stable Coronary Artery Disease in Patients with T2D Mellitus – AHA Scientific Statement).
2020 Episode 6 – Clinical Management of Stable Coronary Artery Disease in Patients with T2D
Mikhail Kosiborod, MD is a Cardiologist, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes as well as quality of care and outcomes. He has authored and co-authored over 220 peer reviewed publications, including scientific statements and position documents. He is involved in the leadership of multiple clinical trials and multi-center registries and is currently the principal investigator of several investigator-initiated, multicenter trials in diabetes and CVD.
Prakash Deedwania, MD, FACC, FAHA, FESC is one of the most recognizable figures in the fields of diabetes, hypertension, heart failure, lipid disorders, ischemic heart disease, rhythm disorders and preventive cardiology where he has authored numerous landmark clinical trials and several clinical practice guidelines. He is a respected leader of several national and international medical societies, having held various positions at the AHA, the American College of Cardiology and the National Health Lung & Blood Institute. He has published over a thousand medical manuscripts, and is on the editorial board of the top medical journals including the Journal of the American College of Cardiology, American Journal of Cardiology, Clinical Cardiology, among many others.
Suzanne V. Arnold, MD, MHA is an Associate Professor of Medicine at the University of Missouri-Kansas City and a cardiologist at Saint Luke’s Mid America Heart Institute. She also completed a cardiovascular outcomes research fellowship through the AHA. Her research centers on the long-term outcomes of patients with CVD, with a particular focus on patients’ quality of life—how to best assess it, what factors influence it and how to improve it. She was the recipient of several research awards, including the Burton Sobel Award for Excellence in Cardiovascular Research at Washington University in St. Louis and the AHA Young Investigator Award.